PLK1 inhibitors appear to be versatile anticancer agents for a variety of cancers, and their recent interplay with immunotherapies (Reda et al, 2022; Zhang et al, 2022) will likely open interesting research avenues for melanoma treatment. The gene discussed is PLK1; the disease is cancer.